Trial
NCT03644550
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Phase IITERMINATEDREGULATORYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Mesothelioma
Intervention
LMB-100
Why stopped
Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-02